Predictors of response in biliary tract cancer
Part of Cancer, Digestive system clinical trials.
This trial is looking at how certain markers in your blood or tissue (biomarkers) might predict how well the combination of Lenvatinib and Pembrolizumab works against advanced biliary tract cancer. If you're already scheduled to receive these two drugs, researchers want to learn more from your samples to help future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced bile duct or gallbladder cancer (called biliary tract cancer).
- Your doctor plans to treat you with a combination of two drugs: Lenvatinib and Pembrolizumab.
- You are 20 years old or older.
- Your activity level is fairly good – you can take care of yourself and may be able to do light work (called ECOG 0-2).
- You agree to give blood or tissue samples for research and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at lab markers (including genetic tests) to predict how people with bile duct cancer respond to treatment. Your answers and samples may help doctors personalize care for bile duct cancer in the future.
This trial tests a combination treatment for biliary tract cancer that is borderline resectable or locally advanced. It combines a chemotherapy infusions directly into the liver (HAIC) with an immunotherapy drug (adebrelimab) and a targeted therapy pill (lenvatinib), aiming to shrink the tumor enough to allow surgery.
This trial tests a new combination of two drugs for advanced bile duct cancer (cholangiocarcinoma) that has not responded to previous treatment. The drugs work with your immune system to attack cancer cells, and may help slow the disease.
This study tests whether adding another drug (lenvatinib or chemotherapy) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for advanced bile duct or gallbladder cancer that has not been treated before. It aims to find a more effective first treatment option.
This Phase 3 study tests whether a combination of lenvatinib, an immunotherapy medicine (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) works better for advanced bile duct cancer that cannot be fully removed by surgery. It may help people live longer or control the cancer for longer.
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.